|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Administration of a CXCL16-neutralizing antibody to KRAS(G12D) mice reduced activation of PI3K signaling to AKT and NF-κB, blocking carcinogenesis.
|
25683115 |
2015 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumorigenesis was measured in the Kras(G12D/+);Ptf1a(Cre/+) mouse model of PDA; these mice were crossed with mice with pancreas-specific disruption of genes encoding PI3K p110α (Pik3ca), p110β (Pik3cb), or RAC1 (Rac1).
|
25311989 |
2014 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Through two novel transgenic mouse models, we show that Twist1 cooperates with Kras(G12D) to markedly accelerate lung tumorigenesis by abrogating cellular senescence programs and promoting the progression from benign adenomas to adenocarcinomas.
|
22654667 |
2012 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the role of oncogenic RAS mutations in pancreatic tumorigenesis, we directed endogenous expression of KRAS(G12D) to progenitor cells of the mouse pancreas.
|
14706336 |
2003 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we demonstrate in an in vivo transgenic model in which atorvastatin reverses and prevents the onset of MYC-induced lymphomagenesis, but fails to reverse or prevent tumorigenesis in the presence of constitutively activated K-Ras (G12D).
|
17622571 |
2007 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
|
24213573 |
2014 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We demonstrated that transient transgenic expression of KRAS(G12V) in putative neural stem and/or progenitor cells induced brain tumorigenesis.
|
25644510 |
2015 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
|
25902334 |
2015 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The data suggest that coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene-induced senescence.
|
26028035 |
2016 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
PIK3CA(H1047R) expression alone failed to promote tumor formation, but dramatically enhanced tumorigenesis initiated by KRAS(G12D).
|
26567140 |
2015 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
To examine how the MYC and K-ras(G12D) oncogenes cooperate for the initiation and maintenance of tumorigenesis, we generated double conditional transgenic tumor models of lung adenocarcinoma and lymphoma.
|
18461184 |
2008 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, genetic targeting of the Nrf2 pathway impairs K-Ras(G12D)-induced proliferation and tumorigenesis in vivo.
|
21734707 |
2011 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We used these mice to investigate a possible cooperative effect of GNAS(R201H) and Kras(G12D) in pancreatic tumorigenesis.
|
26257060 |
2016 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, a more rigorous test of the requirement for Notch signaling in lung oncogenesis, crossing the LSL-KRAS(G12D) mouse model with a transgenic with a similarly inducible global dominant-negative suppressor of Notch activity, LSL-DNMAML (dominant-negative mastermind-like), reveals no evidence of Notch pathway requirement for lung tumor initiation or growth in vivo.
|
21994468 |
2011 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutation in the B RAF at V600E has been well implicated in the carcinogenesis that makes it as an attractive therapeutictarget.
|
28472910 |
2017 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The B-Raf(V600E) mutant, found in 65% of human melanomas, drives constitutive activation of the extracellular signal-regulated kinase (ERK) pathway and is implicated in tumorigenesis.
|
18071315 |
2008 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report that BRAF(V600E) expression in neural progenitors (NPs) is insufficient for tumorigenesis and increases NP cellular differentiation as well as apoptosis.
|
22586120 |
2012 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
A large number of studies in the past decade have tried to dissect the relevance and the function of the V600E mutation in controlling oncogenesis and progression of thyroid cancer.
|
24828987 |
2015 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAF(V600E)-driven signalling and tumorigenesis in mice and human cell settings.
|
24717435 |
2014 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
To determine the occurrence of BRAF V600E gene mutations and copy number changes of all autosome arms and genes known to be frequently altered in tumorigenesis in primary and metastatic conjunctival melanomas (CoMs).
|
21693616 |
2011 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
While the role of BRAF(V600E) in tumorigenesis is well established, its involvement in metastasis that is clinically observed in melanoma patients remains a topic of debate.
|
27210749 |
2016 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The increased incidence of cancer in FDRs of index CRC patients with the p.V600E BRAF mutation may be explained by a genetic predisposition to develop cancer through the serrated pathway of colorectal carcinogenesis.
|
20570909 |
2010 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.
|
28638488 |
2017 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast to other Braf-induced mouse models of tumorigenesis (i.e., melanomas and lung), in which knock-in of Braf(V600E) induces mostly benign lesions, Braf-expressing thyrocytes become transformed and progress to invasive carcinomas with a very short latency, a process that is dampened by treatment with an allosteric MEK inhibitor.
|
21220306 |
2011 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results suggest that the B-Raf activation segment mutations other than V599E reported in colorectal tumors do not necessarily contribute to carcinogenesis by increasing kinase and transforming activities.
|
14678966 |
2003 |